ArticleCNS neuroscience & therapeutics2026
Prediction of Zonisamide Concentration in Pediatric Patients With Epilepsy: A Machine Learning Approach.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo construct and validate prediction models for zonisamide (ZNS) concentration in pediatric patients with epilepsy based on 12 machine learning algorithms, to screen for the optimal algorithm, and to provide a scientific basis for the formulation of individualized ZNS dosing regimens in children.
methodsClinical data of patients who underwent ZNS therapeutic drug monitoring at Kunming Children's Hospital from May 2022 to January 2026 were retrospectively collected and randomly divided into a training set and a test set at a ratio of 7:3. Key predictive variables were determined through a multi-stage feature screening strategy (covering correlation analysis, collinearity diagnosis, univariate analysis, Lasso regression, and random forest algorithm). Based on the selected variables, 12 machine learning regression models were constructed to predict ZNS concentration, and grid search combined with 5-fold cross-validation was employed for parameter optimization and performance evaluation. The coefficient of determination (R
resultsThe modeling cohort of this study enrolled 532 pediatric patients who received zonisamide treatment at the Department of Neurology, Kunming Children's Hospital from May 2022 to May 2024. These patients were randomly divided into a training set (375 cases) and an internal validation set (157 cases) at a ratio of 7:3. Additionally, 436 pediatric patients from the same department of the same hospital from June 2024 to January 2026 were included as an external validation cohort. Comparisons of general clinical data, laboratory indicators, and medication-related data among the groups showed no statistically significant differences (all p > 0.05), indicating that the baseline data were balanced and comparable. The median (interquartile range) ZNS concentrations in the training set, internal validation set, and external validation cohort were 9.65 (8.11, 11.98) μg/mL, 9.93 (8.23, 12.06) μg/mL, and 10.77 (7.67, 13.69) μg/mL, respectively. Through multi-stage feature screening, gender, dosage, age, red blood cell count, concomitant medication status, total protein, uric acid, and platelets were identified as key factors influencing ZNS concentration. Among the 12 constructed machine learning models, the Random Forest (RF) algorithm demonstrated the optimal performance: in the training set, R
conclusionThis study successfully constructed and validated a ZNS concentration prediction model for pediatric patients with epilepsy based on the random forest algorithm. The model demonstrated high precision, strong stability, and good generalization ability. Gender, dose, uric acid, and total protein are core variables influencing ZNS concentration. The findings can provide a reference for the formulation of individualized ZNS dosing regimens in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.